Chatterjee V K, Nagaya T, Madison L D, Datta S, Rentoumis A, Jameson J L
Thyroid Unit, Massachusetts General Hospital, Boston, Massachusetts 02114.
J Clin Invest. 1991 Jun;87(6):1977-84. doi: 10.1172/JCI115225.
Thyroid hormone (T3) resistance is inherited in most cases in an autosomal dominant manner. The disorder is characterized by elevated free thyroid hormone levels and partial resistance to thyroid hormone at the cellular level. Distinct single amino acid substitutions in the ligand binding domain of the beta form of the thyroid hormone receptor have been described in two kindreds with this disorder. We used transient expression assays to characterize the functional properties of these receptor mutants, one containing a Gly to Arg change at amino acid 340 (G340R) and the other a Pro to His change at amino acid 448 (P448H). A nine amino acid carboxy terminal deletion (delta 448-456), analogous to an alteration that occurs in v-erbA, was also studied for comparison with the mutations that occur in the T3 resistance syndrome. None of the receptor mutants were able to mediate thyroid hormone dependent activation (TreTKCAT) or repression (TSH alpha CAT) of reporter genes when compared with the wild type receptor. In addition, the mutants inhibited the activity of normal alpha and beta receptor isoforms when examined in coexpression assays. This activity, referred to as dominant negative inhibition, was manifest with respect to both the positively and negatively regulated reporter genes. Although mutant receptor binding to DNA was unaffected, ligand binding studies showed that the G340R and delta 448-456 mutants failed to bind T3, whereas the P448H mutant bound hormone with reduced affinity (approximately 10% of normal) compared to the wild type receptor. Consistent with this finding, the P448H mutant receptor was partially active at higher T3 concentrations. Furthermore, the dominant negative inhibition elicited by the P448H receptor mutant at higher T3 concentrations was reversed in the presence of high doses of T3. These findings indicate that mutant beta receptors in patients with thyroid hormone resistance have reduced affinity for T3 and are functionally deficient, but impair the activity of normal receptors, thereby providing a mechanism for the dominant mode of inheritance in this disorder.
甲状腺激素(T3)抵抗在大多数情况下以常染色体显性方式遗传。该病症的特征是游离甲状腺激素水平升高以及细胞水平上对甲状腺激素的部分抵抗。在患有这种病症的两个家族中,已经描述了甲状腺激素受体β形式的配体结合域中不同的单氨基酸取代。我们使用瞬时表达分析来表征这些受体突变体的功能特性,其中一个在氨基酸340处含有从甘氨酸到精氨酸的变化(G340R),另一个在氨基酸448处含有从脯氨酸到组氨酸的变化(P448H)。还研究了与v-erbA中发生的改变类似的九个氨基酸的羧基末端缺失(δ448-456),以便与T3抵抗综合征中发生的突变进行比较。与野生型受体相比,没有一个受体突变体能够介导报告基因的甲状腺激素依赖性激活(TreTKCAT)或抑制(TSHαCAT)。此外,在共表达分析中检测时,这些突变体抑制了正常α和β受体同工型的活性。这种活性,称为显性负抑制,在正向和负向调节的报告基因方面均有体现。尽管突变体受体与DNA的结合未受影响,但配体结合研究表明,G340R和δ448-456突变体未能结合T3,而P448H突变体与野生型受体相比,以降低的亲和力(约为正常的10%)结合激素。与这一发现一致,P448H突变体受体在较高T-3浓度下具有部分活性。此外,在高剂量T3存在的情况下,P448H受体突变体在较高T3浓度下引起的显性负抑制被逆转。这些发现表明,甲状腺激素抵抗患者中的突变β受体对T3的亲和力降低且功能缺陷,但会损害正常受体的活性,从而为该病症的显性遗传模式提供了一种机制。